Daiichi Sankyo Company

Cuorips Inc. is a Japanese company focused on the research, development, and commercialization of induced pluripotent stem (iPS) cell-derived cardiomyocyte sheets and cell therapeutic products. Founded in 2017, Cuorips, formerly known as Cuore Inc., operates from its headquarters in Chuo, Japan, with an additional office in Osaka. The company aims to advance medical care by leveraging cutting-edge technology to create innovative solutions in the field of regenerative medicine.

Cuorips Inc. is a Japanese company focused on the research, development, and commercialization of induced pluripotent stem (iPS) cell-derived cardiomyocyte sheets and cell therapeutic products. Founded in 2017, Cuorips, formerly known as Cuore Inc., operates from its headquarters in Chuo, Japan, with an additional office in Osaka. The company aims to advance medical care by leveraging cutting-edge technology to create innovative solutions in the field of regenerative medicine.

Cuorips Inc. is a Japanese company focused on the research, development, and commercialization of induced pluripotent stem (iPS) cell-derived cardiomyocyte sheets and cell therapeutic products. Founded in 2017, Cuorips, formerly known as Cuore Inc., operates from its headquarters in Chuo, Japan, with an additional office in Osaka. The company aims to advance medical care by leveraging cutting-edge technology to create innovative solutions in the field of regenerative medicine.

Im Co.,Ltd. manufactures and sells cosmetics and over-the-counter drugs. The company offers skin care products, including moisturizing lotions and creams, make up removers, face washes, makeup primers with sun protection, and lip moisturizing treatments; and beauty supplements.

Ambit Biosciences is a privately-held biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating cancer, inflammatory diseases, and other conditions. The company's lead compound, AC220, is a selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various indications. The clinical pipeline also includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. In addition, Ambit has several preclinical candidates, including CEP-32496, a BRAF inhibitor that has been licensed to Cephalon. Through its innovative research, Ambit aims to improve treatment outcomes for patients suffering from cancer.

Orphan Disease Treatment Institute develops a treatment for Duchenne muscular dystrophy.

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company based in Redwood City, California, that specializes in the development, manufacture, and marketing of biosimilar therapeutics. It primarily targets the oncology and inflammatory disease markets with its product offerings. The company's flagship product, UDENYCA, is a biosimilar to Neulasta, designed to stimulate the production of granulocytes to enhance the body’s infection-fighting capabilities. Coherus is also advancing several other biosimilar candidates, including those for Humira and Enbrel, which have completed Phase III clinical studies. Additionally, the company is working on biosimilars for other biologics, including ranibizumab and aflibercept, as well as a small-molecule drug for metabolic conditions. Coherus BioSciences was founded in 2010 and has established various license agreements to support its product development initiatives.

Plexxikon, Inc. is involved in the discovery and development of small molecule pharmaceuticals aimed at treating various human diseases. The company's product pipeline includes PLX204, targeting diabetes, and PLX4032, designed for melanoma and colorectal cancer. Additionally, it has PLX5568 kinase inhibitors that address pain, polycystic kidney disease, rheumatoid arthritis, metastatic breast cancer, and renal disease. Plexxikon is engaged in both clinical and preclinical stage programs across multiple therapeutic areas, including metabolic diseases like obesity, oncology with a focus on osteolytic metastatic disease, and central nervous system disorders such as multiple sclerosis. The company also explores treatments for inflammation-related conditions, including systemic lupus erythematosus and inflammatory bowel disease, as well as cardiovascular issues like hypertension and atherosclerosis.

Ranbaxy Laboratories Limited is a pharmaceutical company established in 1961, specializing in the production of generic medicines and a variety of pharmaceutical products. With a presence in 49 countries and manufacturing facilities in 11, the company serves customers across approximately 125 countries. Ranbaxy's product portfolio includes around 5,000 stock-keeping units (SKUs), which encompass generic pharmaceuticals, branded generics, and active pharmaceutical ingredients (APIs). The company emphasizes research and development, focusing on novel drug delivery systems and new drug discovery in areas such as infectious diseases, metabolic disorders, and oncology. Notably, Ranbaxy is involved in developing oral controlled-release products and pursuing innovative therapies through collaborations with academic institutions. In June 2008, Ranbaxy formed a strategic alliance with Daiichi Sankyo Company Ltd., enhancing its capabilities in the pharmaceutical sector. The company also has a licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product Neuronox, demonstrating its diverse product offerings beyond traditional pharmaceuticals. Through its commitment to providing quality and affordable medications, Ranbaxy continues to play a significant role in the global healthcare landscape.

U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in targeted cancer drug development. Established in July 2001, the company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Professor Axel Ullrich. Since May 2008 U3 Pharma belongs to DAIICHI Sankyo Co. Ltd., one of the top 20 leading pharmaceutical companies worldwide and no. 3 in Japan. Being part of this global environment, U3 Pharma is striving to provide patients around the world with innovative antibody-based therapeutics.

SymBio Pharmaceuticals Limited is a biopharmaceutical company based in Tokyo, Japan, focused on the research, development, manufacturing, and marketing of pharmaceutical drugs, primarily in the fields of oncology and hematology. The company develops various anti-cancer agents, including Treakisym, which is used to treat non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia, and is currently undergoing Phase III trials for relapsed/refractory diffuse large B-cell lymphoma. Additionally, SymBio is working on several other drug formulations, including SyB L-1701, SyB L-1702, and Rigosertib SyB-C-0501, as well as SyB L-1101 and SyB C-1101 for higher-risk myelodysplastic syndromes. The company also has a candidate, SyB V-1901, aimed at treating infectious diseases. SymBio Pharmaceuticals operates primarily in Japan, South Korea, China, Hong Kong, Taiwan, and Singapore.